London, March 2, 2026, 08:25 GMT — Regular session.
Haleon PLC (HLN) hovered near flat in early Monday action in London, edging 0.2 pence lower to 405.5p as of 0811 GMT. The stock moved in a tight range, 402.7p at the low to 408.3p at the high. FTSE 100 was off roughly 0.9%.
Shares in the consumer healthcare group finished Friday up 2.9% at 4.06 pounds, outpacing the wider market. Yet, the stock continues to digest a string of reports tied to its 2026 outlook, stirring questions about growth prospects in its key market.
Last week, Haleon projected 3% to 5% organic revenue growth for 2026 and set aside 500 million pounds for buying back shares. The company also put forward a final dividend of 4.9p a share, following a reported 3% organic revenue gain and 1.9 billion pounds in free cash flow for 2025.
Organic growth excludes the effects of currency swings, acquisitions, and disposals. It’s a key metric for investors sizing up real demand for products like over-the-counter medicines, toothpaste, or vitamins.
Brian McNamara, the chief executive, told Reuters he’s counting on tweaks to leadership and distribution to push U.S. growth this year, predicting, “by 2027 we’ll be back to our medium-term growth range.” Chris Beckett at Quilter Cheviot noted the strain on American consumers: “Many (U.S.) households feel financially stretched, and that pressure is now showing up even in over-the-counter medicines.” Reuters
Jefferies’ David Hayes didn’t mince words after the numbers landed. “This is not good enough we fear,” he said, highlighting the guidance drop to “3-5%.” Investing
Dividend timing is lining up too. According to a filing, Haleon’s final payout lands on May 14, with April 9 as the ex-dividend date for ordinary shares and April 10 as the record date.
Here’s the risk: if U.S. demand remains sluggish and competitors ramp up promotions, Haleon could be stuck sacrificing margin just to chase volume. That scenario would flip the growth range from a floor to a ceiling.
The stock sits wedged between short-term wariness and hopes tied to buybacks. A new signal on U.S. volumes has the potential to steer things quickly.
April 29 is circled as the next key date: Haleon’s first-quarter trading update is set to land alongside its annual general meeting.
